

Substitute Form PTO-1449
(Revised)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
16596-018001Application No.
10/076,074**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR 1.98(b))

Applicant
Matthew C. Coffey, et al.Filing Date
February 15, 2002Group Art Unit
1642**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
BGL	AQ	Bryson, J.S. and D.C. Cox, "Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia", Cancer Immunol. Immunother. 26: 132-138 (1988)
	AR	
	AS	
	AT	

Examiner Signature

Baogun Li

Date Considered

11/02/2004

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified) SEP 13 2004 PATENT OFFICE (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 16596-018001	Application No. 10/076,074
	Information Disclosure Statement by Applicant (Use several sheets if necessary)			
	Applicant Matthew C. Coffey, et al.		Filing Date February 15, 2002	Group Art Unit 1642

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AI							
	AJ							
	AK							
	AL							
	AM							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
58C	AN	Steele, T. A. and Cox, D. C., "Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporin", Cancer Biotherapy 10(4): 307-315 (1995).
	AO	Rayter, S. I. et al., "p21 ^{ras} mediates control of IL-2 gene promoter function in T cell activation", EMBO Journal 11(12): 4549-4556 (1992).
	AP	Baldari, C. T., et al., "Interleukin-2 promoter activation in T-cells expressing activated Ha-ras", J. Biological Chemistry 267(7): 4289-4291 (1992).
	AQ	Umezawa K. et al., "Isolation of a new vinca alkaloid from the leaves of <i>Ervatimia microphylla</i> as an inhibitor of <i>ras</i> functions", Anticancer Research 14: 2413-2418 (1994).
	AR	Umezawa K. et al., "Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice", Drugs Exptl. Clin. Res. 22(2): 36-40 (1996).

Examiner Signature <i>Naogen Li</i>	Date Considered <i>11/01/2004</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	